Dr. Wang Discusses FLT3 Mutations in AML
Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses FLT3 mutations in acute myeloid leukemia (AML).
In a study of patients with FLT3-mutated AML, crenolanib was combined with standard chemotherapy. There was an initial high response rate, and the drug was fairly well tolerated.
There is a lot of heterogeneity in the FLT3 mutations that AML patients can present with, says Wang. Additionally, there are data suggesting that these mutations can predict resistance to other TKIs.